COMPANY
Company History
COMPANY
Company History
Curacle, a Biopharma with Innovative Technology,
Global Competitiveness, and Sustainable Growth Potential
2024
09 e-Poster presentation of CU06 diabetic macular edema U.S. phase 2a clinical trial results at EURETINA 2024
07 Co-R&D agreement with MabTics for antibody therapeutics for refractory vascular diseases
07 Oral presentation of CU06 diabetic macular edema U.S. phase 2a clinical trial results at ASRS 2024 (The American Society of Retina Specialists)
05 Poster presentation of CU06 diabetic macular edema U.S. phase 1 clinical trial results at ARVO 2024 (The Association for Research in Vision and Ophthalmology)
04 CU06 (Diabetic Macular Edema), U.S. Phase 2a Clinical Trial CSR(Clinical Study Reports) received
03 Establishment of Curacle Advanced Institute of Technology (CAIT)
02 CU06 (Diabetic Macular Edema), U.S. Phase 2a Clinical Trial Topline Data Announced
2023
12 CU104 (Ulcerative Colitis), Phase 2 IND application approved by the Europe
09 Co-development agreement with CAND to develop treatments for kidney disease of companion animals
07 Signed on MOU with STANDIGM, an artificial intelligence (AI) drug discovery company
06 Signed on MOU with MabTics, an antibody therapeutics company
06 CU104 (Ulcerative Colitis), Phase 2 IND application approved by the FDA
06 Signed an MOU with Center for Companion Animal New drug Development(CAND)
04 Signed MOU with College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University
2022
12 Acquired high-tech product certification from the Ministry of Trade, Industry and Energy
12 Grand Prize at the 2022 Korea Value Management Award by HANKOOKILBO
11 Acquired R&D type venture enterprise certification
09 CU06(diabetic macular edema), Phase 2a IND application approved
09 New CFO·Vice President Appointed
07
CU01(diabetic nephropathy), Phase 2a IND application approved
06
Computer-Aided drug design
CU06, Finalized CU06 Phase1 CSR
04 Relocated research center and welcomed Seocho Headquarters phase
01 Established 2nd bio research center
00 Poster presentation of CU06 US Diabetic Macular Edema phase 1 clinical trial results at ARVO 2024 (The Association for Research in Vision and Ophthalmology)
2021
11 New CEO Appointed
10 CU06, Out-licensed to ophthalmology company Thea for 200 Billion USD
09 CU01 (Diabetic nephropathy), Submitted Phase 3 IND
07 Listed on KOSDAQ (365270)
03 CU06 (Diabetic Macular Edema), Phase 1 IND approved by FDA (NCT04795037)
03
Passed the technical evaluation for Special Technology Assessment Track listing(grade: AA, A)
CU01 (Diabetic nephropathy), Confirmed safety and efficacy in Phase 2a clinical trial
01
Signed MOU with College of Pharmacy & Institute of Pharmaceutical Science and Technology Research, Korea University
2020
12
Signed research agreement with Severance Hospital
11
CU06 (Vessel Protector & Zipper) U.S. Clinical DP Production Completed (cGMP)
Signed research agreement with Yonsei University and opened industry-academic cooperation biolab
Inno-Biz certification (certification number: 200605–01197)
10
Introduction and Transition of Electronic Securities System
Funding raised (US$ 4 million)
08
Awarded ‘Bio-Tech Science Innovation Award’ from “2020 6th Korea Leading Enterprise Awards”
CU01 (Diabetic Nephropathy), Completed Test Subject Recruitment for Clinical 2a Phase
CU03 (Wet AMD), Completed Clinical 2a Phase tolerability Assessment, Recruited additional 60 subjects
Appointment of stock transfer agent (Korea Securities Depository)
06 Signed research agreement for formulation development with LS Pharma
04
Startups Research Infra Utilization (Research Focused) Grant awarded by the Ministry of SMEs
CU06, Pharmaceutical Industry Global Advancement Supporting Grant awarded by the Ministry of Health and Welfare
03 CU06, signed CMO service contract with Yuhan Chemical (South Korea) for cGMP DS production of FDA Phase 1 study
01 Established Bio & Analytical Laboratory at Pangyo 2nd Techno Valley
2019
12 CU03 (Wet AMD), Phase 2a IND approved by Ministry of Food and Drug Safety(MFDS)
11
Signed Consultation contract with BL&H (USA) for global BD
Funding raised (US$ 7.1 million)
10
Relocated headquarters to Pangyo 2nd Techno Valley
CU06, signed CMO service contract with Patheon (USA) for formulation study & cGMP DP production
07 Samsung Securities selected as underwriter for IPO
06 CU06, Signed CRO service contract with Covance (UK) for global GLP nonclinical study
05 CU01 (Diabetic Nephropathy), Phase 2a IND approved by Ministry of Food and Drug Safety(MFDS)
04 CU06, Signed Technology transfer agreement of Vessel Protector & Zipper from Yonsei University
01 Relocated R&D center (from Daegu Gyeongbuk Medical Innovation Foundation (DGMIF) to Korea Research Institute of Chemical Technology (KRICT), Daejeon)
2018
12 Nominated as a membership business of the Korea Research Institute of Chemical Technology (KRICT)
11 Funding raised (US$ 9.0 million)
10 Relocated headquarters (Woorim W-city at Pangyo)
03 CU05 (Lung Cancer), Grant awarded by the Ministry of Science and ICT for the biomedical technology development business project
01 CU02 (NASH & Obesity), Grant awarded by the Ministry of Science and ICT for the biomedical technology development business
2017
10 CU04 (immunotherapy), Grant awarded by Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF) New Drug Development Center for optimization support
08 CU02 (NASH & Obesity), Signed Technology transfer agreement from Gwangju Institute of Science and Technology (GIST), Korea Advanced Institute of Science and Technology (KAIST) & Kyungpook National University (KNU)
06 CU01, Grant awarded from the Ministry of Trade, Industry and Energy
05 CU01 Signed research contract with Mcnulty for formulation development
04 CU05, Signed research agreement with College of Pharmacy, Gachon University
03 CU03 (Macular Degeneration), Signed technology transfer agreement from Korea Institute of Oriental Medicine (KIOM)
02
CU01 (Renal Fibrosis), Signed technology transfer agreement from Kyungpook National University
CU05 (Lung Cancer), Signed technology transfer agreement from Yonsei University
01 Established R&D center at Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF) certified as affiliated research institute
2016
11
Registered as a venture business (No. 20160300500)
Relocated headquarters (Innovalley at Pangyo)
10 Funding raised (US$ 1.5 million)
05 Established Curacle Co., Ltd. (Gangnam, Seoul)